| Dr David Alan Tack, MD | |
|
1100 S Carson St, Carson City, NV 89701-5232 | |
| (775) 883-7811 | |
| Not Available |
| Full Name | Dr David Alan Tack |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 25 Years |
| Location | 1100 S Carson St, Carson City, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124032990 | NPI | - | NPPES |
| 11209 | Other | NV | NV STATE MED. LIC # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 11209 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clemmensen, Adams, And Tack Psc | 1052398591 | 8 |
News Archive
Celerion, the premier provider of innovative early stage clinical research solutions, announces the launch of a new Hybrid Phase I/ ECG Core lab. The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion's global Phase I clinical network. Celerion's highly automated approach employs cutting-edge technology to perform automated measurement of ECG recordings, thereby minimizing cardiologist review and providing clients with faster access to data.
The Hampton University Proton Therapy Institute's first group of patients completed their course of treatment for prostate cancer.
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
The MOMAT research group from Universidad Complutense de Madrid has worked with Universidad de Almería, to develop a mathematical model that simulates the impact of SARS-CoV-2 strains and vaccines together, combined with many other biological and social processes in the propagation of COVID-19.
In a presentation at the annual meeting of the Heart Failure Association of the European Society of Cardiology, and in a simultaneous publication in Circulation, investigators from Brigham and Women's Hospital presented evidence that a next-generation cardiac pump device not only improves long-term outcomes but may also decrease cost of care over time for heart failure patients.
› Verified 9 days ago
| Entity Name | Clemmensen, Adams, & Tack Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780852368 PECOS PAC ID: 1052398591 Enrollment ID: O20040702000297 |
News Archive
Celerion, the premier provider of innovative early stage clinical research solutions, announces the launch of a new Hybrid Phase I/ ECG Core lab. The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion's global Phase I clinical network. Celerion's highly automated approach employs cutting-edge technology to perform automated measurement of ECG recordings, thereby minimizing cardiologist review and providing clients with faster access to data.
The Hampton University Proton Therapy Institute's first group of patients completed their course of treatment for prostate cancer.
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
The MOMAT research group from Universidad Complutense de Madrid has worked with Universidad de Almería, to develop a mathematical model that simulates the impact of SARS-CoV-2 strains and vaccines together, combined with many other biological and social processes in the propagation of COVID-19.
In a presentation at the annual meeting of the Heart Failure Association of the European Society of Cardiology, and in a simultaneous publication in Circulation, investigators from Brigham and Women's Hospital presented evidence that a next-generation cardiac pump device not only improves long-term outcomes but may also decrease cost of care over time for heart failure patients.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Alan Tack, MD 227 St Albans Pl, Carson City, NV 89703-4546 Ph: (775) 841-5259 | Dr David Alan Tack, MD 1100 S Carson St, Carson City, NV 89701-5232 Ph: (775) 883-7811 |
News Archive
Celerion, the premier provider of innovative early stage clinical research solutions, announces the launch of a new Hybrid Phase I/ ECG Core lab. The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion's global Phase I clinical network. Celerion's highly automated approach employs cutting-edge technology to perform automated measurement of ECG recordings, thereby minimizing cardiologist review and providing clients with faster access to data.
The Hampton University Proton Therapy Institute's first group of patients completed their course of treatment for prostate cancer.
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
The MOMAT research group from Universidad Complutense de Madrid has worked with Universidad de Almería, to develop a mathematical model that simulates the impact of SARS-CoV-2 strains and vaccines together, combined with many other biological and social processes in the propagation of COVID-19.
In a presentation at the annual meeting of the Heart Failure Association of the European Society of Cardiology, and in a simultaneous publication in Circulation, investigators from Brigham and Women's Hospital presented evidence that a next-generation cardiac pump device not only improves long-term outcomes but may also decrease cost of care over time for heart failure patients.
› Verified 9 days ago
Dr. Jay Stanley Adams, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: Carson Dermatology, 1100 South Carson Street, Carson City, NV 89701 Phone: 775-883-7811 Fax: 775-883-7871 | |
Dr. Ruth Elizabeth Adams, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1100 S Carson St, Carson Dematology, Carson City, NV 89701 Phone: 775-883-7811 Fax: 775-883-7871 | |
Charles Clemmensen, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1100 S Carson St, Carson City, NV 89701 Phone: 775-883-7811 |